AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insulet delivered Q3 2025 results surpassing analyst predictions due to strong Omnipod expansion. The company boosted full-year guidance, with shares rallying and guidance continually raised. The stock is now undervalued at $365.96, with room for upside based on updated growth and margin expectations. However, reliance on a single core product and global competition pose risks to Insulet's growth story.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet